drugset
drugset / Trial / NCT04220632

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

NCT04220632 ↗

Phase 1/2 Terminated 1 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate itacitinib in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Timeline

Start
2020-06-18
Primary completion
2020-10-10
Completion
2020-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral
Background Methylprednisolone Other / unclassified — —
Background Prednisone Other / unclassified — Oral

Indications

acute graft versus host disease